Nav: Home

Ovarian cancer patients undertested for mutations that could guide clinical care

April 09, 2019

Fewer than a quarter of breast cancer patients and a third of ovarian cancer patients diagnosed between 2013 and 2014 in two states underwent genetic testing for cancer-associated mutations, according to a study by researchers at the Stanford University School of Medicine and several other organizations.

The findings indicate that substantial gaps exist between national guidelines for testing and actual testing practices. In particular, the findings show that too few women with ovarian cancer are tested for the presence of mutations that could be used to guide health care decisions.

The study looked at about 83,000 women diagnosed with breast or ovarian cancer in California and Georgia in 2013 and 2014.

"We initiated this study -- the largest population-based study of multigene testing in breast and ovarian cancer patients -- because we wanted to see what cancer genetic testing and results looked like in the real world," said Allison Kurian, MD, MSc, associate professor of medicine and of health research and policy at Stanford. "Now we can see that women with ovarian cancer are dramatically undertested. We also learned that between 8 and 15 percent of women with breast or ovarian cancer carry cancer-associated mutations that could be used to drive care decisions and influence family members' health care and screening choices."

Kurian shares lead authorship of the study, which will be published online April 9 in the Journal of Clinical Oncology, with Kevin Ward, PhD, MPH, assistant professor in epidemiology at Emory University. Lynne Penberthy, MD, MPH, associate director for the National Cancer Institute's Surveillance Research Program, and Steven Katz, MD, MPH, professor of medicine and of health management and policy at the University of Michigan, are co-senior authors.

Changing guidelines

Researchers have known for decades that inherited mutations or variations in certain genes, notably BRCA1 and BRCA2, increase the risk of developing breast and ovarian cancers. Genetic tests for mutations in BRCA1 and BRCA2 have been available for several years. But since 2013, genetic tests have incorporated many more potential cancer-susceptibility genes, and results have become much more complicated.

"Integrating genetic counseling and testing into the management of cancer after diagnosis has become much more challenging for patients and their clinicians," Katz said.

National guidelines recommend that all women with the most common type of ovarian cancer be tested for the presence of cancer-associated mutations; guidelines for testing breast cancer patients have been less expansive. Although the guidelines for genetic testing have expanded to include more patients diagnosed with breast or ovarian cancer and the more extensive multigene panel tests, it's not been clear to what degree these guidelines are followed in real-world clinical settings. Furthermore, the prevalence of known cancer-associated mutations in breast and ovarian cancer patients who are racial or ethnic minorities, as well as in the overall population, is unknown.

For the study, the researchers tapped the National Cancer Institute's Surveillance, Epidemiology and End Results Program, which tracks cancer diagnoses and outcomes in large populations across the United States. They linked data on cancer cases in California and Georgia with data from four laboratories conducting the majority of cancer genetic testing from 2013 to 2014. They found that only 24.1 percent of 77,085 women diagnosed with breast cancer and 30.9 percent of 6,001 diagnosed with ovarian cancer underwent any genetic testing.

Disparities in genetic testing

The researchers also observed disparities in testing, particularly among ovarian cancer patients. Although nearly 34 percent of non-Hispanic white women were tested, only about 22 percent of black women and 24 percent of Hispanic women were tested. Income and insurance status played a role in the prevalence of testing among women with ovarian cancer from all racial and ethnic groups, the researchers found. About 20 percent of patients with Medicare were tested compared with about 34 percent of patients with other forms of health insurance. Testing prevalence decreased to about 20 percent in areas where residential poverty equaled or surpassed 20 percent, and it was about 38 percent in regions where the poverty level was less than 10 percent.

The researchers found that among women with breast cancer in the study who underwent testing for a panel of guideline-designated genes, the prevalence of mutation variants of unknown significance was much higher in minority patients: 28.5 percent, 26.6 percent and 19.3 percent in African-American, Asian and Hispanic patients, respectively, versus 14.5 percent in non-Hispanic whites. The prevalence of pathogenic variants also varied along racial and ethnic lines.

"These differences underscore the need to improve the clarity of genetic test results, especially for racial or ethnic minority patients," Kurian said.
-end-
Researchers from Information Management Services Inc. and the University of Southern California, as well as other researchers from the National Cancer Institute, also contributed to the work.

The research was supported by the National Institutes of Health (grants P01CA163233 and R01CA225697), the California Department of Public Health, the Centers for Disease Control and Prevention and the Cancer Registry of Greater California.

Stanford's departments of Medicine and of Health Research and Policy also supported the work.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med.stanford.edu/school.html. The medical school is part of Stanford Medicine, which includes Stanford Health Care and Stanford Children's Health. For information about all three, please visit http://med.stanford.edu.

Print media contact: Krista Conger at (650) 725-5371 (kristac@stanford.edu)

Broadcast media contact: Margarita Gallardo at (650) 723-7897 (mjgallardo@stanford.edu)

Stanford Medicine

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
More Breast Cancer News and Breast Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...